Drugs / human epidermal growth factor
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07359924 | Feb → Aug 2022 | skin atrophy | Poznan University of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human epidermal growth factor | “Formulation 2: base formulation with human epidermal growth factor (EGF)” NCT07359924 ↗ |
| Known as | EGF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07359924 ↗ |
| Modality | Protein / enzyme biologic | “additional growth factor EGF” NCT07359924 ↗ |
| Route | Topical | “Daily skin application for the following 4 weeks at the same place according to the instruction” NCT07359924 ↗ |